NASDAQ$MLAB

Mesa Laboratories Inc · Q1 2025 earnings

Q1 2025 earnings · · Investor relations

Briefing

Mesa Labs reported first quarter results with revenue increase and strategic traction.

Mesa Labs reported a successful start to its first quarter of fiscal year 2025, with revenues increasing by 14.9% and operating income increasing by 940%. The company saw positive momentum in revenues, orders, profitability, and debt levels.

  • Revenues increased by 14.9% compared to the prior year.
  • Non-GAAP core organic revenue growth was 3.0%.
  • Operating income increased by 940%.
  • Non-GAAP adjusted operating income excluding unusual items increased by 47.0%.

Headline financials

Total Revenue

$58.2M

Previous: $50.6M+14.9%
EPS

$0.62

Previous: $1.77-65.0%
Non-GAAP AOI

$14M

No prior period
Non-GAAP AOI ex Unusual

$15.3M

No prior period
Non-GAAP AOI Margin

26.4%

No prior period
Capital Expenditures

-$891K

Previous: -$270K-230.0%
Free Cash Flow

$9.54M

Previous: $9.67M-1.3%
Net Income

$3.39M

Previous: -$549K+717.1%
Operating Income

$5.58M

Previous: -$664K+940.4%
Gross Profit

$37.2M

Previous: $31.2M+19.5%
Cash & Equivalents

$28.5M

Previous: $32.4M-12.1%
Total Assets

$440M

Previous: $643M-31.5%
R&D Expense

$4.74M

No prior period
Stock-Based Comp

$2.93M

Previous: $2.97M-1.3%

Revenue & EPS history

Mesa Labs · Revenue · Quarterly

$58.2M

Q1 2025+14.9%vs Q1 2024
Beat estimate in 7 of 15 quarters(47%)
ActualEstimate

Revenue by segment

Mesa Labs · $63.7M total across 4 segments · Q4 2026

  • Sterilization and Disinfection Control
    $29.1M
  • Calibration Solutions
    $13.6M
  • Clinical Genomics
    $12.2M
  • Biopharmaceutical Development
    $8.85M

Forward guidance

The company is hopeful that its biopharmaceutical related end markets will continue the strength exhibited in 4Q24 and 1Q25 and will work diligently so that its differentiated products, strategic initiatives and the Mesa Way operating model enable it to outperform in any market scenario.

Tailwinds

  • Biopharmaceutical related end markets are expected to continue the strength exhibited in 4Q24 and 1Q25.
  • Differentiated products.
  • Strategic initiatives.
  • Mesa Way operating model.
  • Strong orders in life sciences vertical which also drove an increase in backlog in the legacy SDC business.

Headwinds

  • Headwinds in China from their economic slowdown.
  • Impacts of the corruption campaign in the healthcare sector.
  • Elongated sales cycles in the US driven by uncertainty in the LDT regulatory environment.
  • Gross profit percentage for the quarter contracted by 500 bps versus the prior year primarily due to the impact of non-cash inventory step-up purchase accounting charges from GKE.
  • Asia Pacific team delivered on their one Mesa strategy to drive positive overall organic growth in the region

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-0.1%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.1%

Avg return

30 days after

54%

35 / 65 earnings

Positive

+26.6%

Q2 2023

Best reaction

-24.9%

Q1 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-15.0%-1.3%
Q3 2026+8.7%+15.9%+8.8%
Q2 2026+2.1%+6.7%+3.7%
Q1 2026-24.9%-16.0%-15.9%
Q4 2025-9.3%-13.5%-12.8%
Q3 2025+2.5%+10.3%+3.2%
Q2 2025-11.4%-16.2%-7.6%
Q1 2025+5.8%+11.8%+13.4%
Q4 2024+13.3%+5.5%-3.4%
Q3 2024+2.0%-0.2%+18.9%
Q2 2024+0.1%-8.8%+2.0%
Q1 2024+8.0%+10.3%+11.4%
Q4 2023-2.2%-7.7%-11.7%
Q3 2023-7.4%-8.6%-13.5%
Q2 2023+26.6%+31.2%+39.1%
Q1 2023-5.5%-10.7%-23.5%
Q4 2022-3.7%-2.7%-6.1%
Q3 2022-3.9%-2.0%-5.8%
Q2 2022+4.0%+1.4%-0.1%
Q1 2022+0.4%-1.4%-3.8%
Q4 2021+4.7%+6.4%+9.6%
Q3 2021+0.9%-0.4%-5.2%
Q2 2021-0.4%+2.7%+2.1%
Q1 2021+2.0%-1.5%-1.4%
Q4 2020-5.7%-6.5%-18.6%
Q3 2020-7.2%-2.4%-13.9%
Q2 2020-0.2%-4.7%+3.3%
Q1 2020+6.6%+7.0%-7.3%
Q4 2019-21.1%-19.3%-2.3%
Q3 2019+0.6%+3.4%+2.2%
Q2 2019+0.9%+3.0%+20.4%
Q1 2019-2.7%-0.3%+3.5%
Q4 2018+16.3%+15.4%+31.3%
Q3 2018-5.1%-14.2%-8.0%
Q2 2018-17.2%-19.7%-19.7%
Q1 2018+5.2%+1.6%-2.5%
Q4 2017-6.5%-13.3%-12.3%
Q3 2017+6.4%+1.4%+5.2%
Q2 2017-1.3%-0.8%-1.1%
Q1 2017-4.3%-10.4%-10.5%
Q4 2016+12.7%+26.5%+23.1%
Q3 2016-4.8%
Q2 2016+1.9%
Q1 2016+13.3%
Q4 2015+2.1%
Q3 2015+0.8%
Q2 2015+10.4%
Q1 2015-2.0%
Q4 2014-4.0%
Q3 2013-0.2%
Q3 2014-0.2%
Q2 2014-0.1%
Q1 2014-3.5%
Q4 2013-0.2%
Q2 2013-1.8%
Q1 2013-0.8%
Q4 2012+2.5%
Q3 2011+1.3%
Q3 2012+1.3%
Q2 2011+1.5%
Q2 2012+1.5%
Q4 2011+0.0%
Q1 2011+0.0%
Q1 2012+0.0%
Q4 2010+0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro